Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant
More patients will use LOW-dose direct oral anticoagulants (DOACs) long-term to prevent recurrent venous thromboembolism (VTE).
We're used to giving warfarin or a DOAC (Eliquis, etc) for 3 months for patients who have a VTE due to a short-term risk such as surgery or minor trauma.
And we know to use long-term anticoagulation to prevent a VTE recurrence for most patients at high risk...such as those with active cancer or a clotting disorder.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote